-transparent.png){kind=logo}
Lipoprotein (a) [Lp(a)] has been recognized for nearly 30 years, and increasingly, associated with the processes of atherogenesis and thrombogenesis. Despite this, the physiological and pathological function (and factors that influence levels) of Lp(a) remain largely unknown. Most experimental evidence supporting the mechanisms of vascular disease, thrombogenesis and atherogenesis have been generated in vitro, and to date, no in vivo confirmation exists. There is also a lack of sound evidence for Lp(a) as a risk factor in prospective as opposed to case-controlled studies. A fuller understanding of Lp(a) is still required in the molecular biology of atherogenesis and thrombogenesis.
G Y Lip, and
A F Jones
January 2007,
Medicinski pregled,
G Y Lip, and
A F Jones
January 2004,
Annals of medicine,
G Y Lip, and
A F Jones
September 1989,
Nature,
G Y Lip, and
A F Jones
November 1990,
Atherosclerosis,
G Y Lip, and
A F Jones
January 1972,
Proceedings of the Rudolf Virchow Medical Society in the City of New York,
G Y Lip, and
A F Jones
January 1981,
Terapevticheskii arkhiv,
G Y Lip, and
A F Jones
January 1995,
Annals of the New York Academy of Sciences,
G Y Lip, and
A F Jones
May 1984,
Wiener klinische Wochenschrift,
G Y Lip, and
A F Jones
June 1965,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
G Y Lip, and
A F Jones
January 1963,
Federation proceedings,
